AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities ...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

Britain on Monday hit back at AstraZeneca over the collapse of a 450 million pound ($558.5 million) investment, saying the drugmaker had scaled back the research and development portion of its plans, ...

UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of p11,500.00. The company’s shares opened today at p11,242.00.

The existing facility will continue to operate and no jobs are at risk. The government said a “change in the make-up of the investment” proposed by AstraZeneca, which is headquartered in ...

An AstraZeneca spokesman said: “Following protracted discussions with the Government, we are no longer pursuing our planned investment at Speke. “Several factors have influenced this decision ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to address concerns over its business in China than on its earnings report alone.

BRITISH pharmaceutical giant AstraZeneca said on Friday (Jan 31 ... “Following protracted discussions with the government, we are no longer pursuing our planned investment” for Speke in Liverpool, ...

Confirming the reversal on Friday, a spokesperson for AstraZeneca said: "Following discussions with the current Government, we are no longer pursuing our planned investment in Speke. "Several factors ...

Select listed pharmaceuticals companies including Pfizer Ltd, Novartis India Ltd, AstraZeneca Pharma India Ltd and GSK Pharmaceuticals Ltd shall be the beneficiaries of the budget announcements ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.